MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phas…
Biotechnology
CH, Zug [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared MoonLake Immunotherapeutics (MLTX) to it's peer group, including competitors as well as it's industry. All monetary values in mil. except volume - volume is in thousands.
| Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 38,440.61 | 13,273.33 | 613.99 | 322.10 | -1,094.48 | 0.00 | 24.8797 | 43.32 | -0.8064 | -20.1849 | -0.08 | -0.07 | 5.9617 | - - | ||
| Maximum | - - | - - | - - | 1,535,067.00 | 609,984.00 | 35,800.00 | 99,050.00 | 5,421.00 | 0.02 | 1,336.3467 | 2,849.43 | 3.0051 | 85.3485 | 0.38 | 8.35 | 37.1953 | - - | ||
| Minimum | - - | - - | - - | 0.00 | 0.00 | -10,603.00 | -56,335.00 | -50,658.00 | 0.00 | -164.8536 | -132.82 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0844 | - - | ||
| Nuvalent, Inc. NUVL | 93.66 | 0.93 1.00% | 52 vs. 535 | 6,654.00 | 0.00 | -44.00 | -36.00 | -330.00 | -0.6900 | -27.7942 | 0.0000 | 0.0000 | 0.0000 | -0.0659 | -0.0628 | 20.6970 | 71.00 | ||
| Structure Therapeutics Inc. GPCR | 31.65 | 1.55 5.15% | 246 vs. 713 | 1,812.00 | 0.00 | -26.00 | -34.00 | -232.00 | -0.5600 | -18.2892 | 0.0000 | 0.0000 | 0.0000 | -0.0606 | -0.0569 | 18.5046 | 57.00 | ||
| Akero Therapeutics, Inc. AKRO | 31.47 | 0.27 0.87% | 133 vs. 549 | 2,196.00 | 0.00 | -53.00 | -35.00 | -627.00 | -0.9000 | -6.6902 | 0.0000 | 0.0000 | 0.0000 | -0.0630 | -0.0585 | 29.8643 | 69.00 | ||
| Arcellx, Inc. ACLX | 88.64 | 1.43 1.63% | 29 vs. 539 | 4,793.00 | 39.00 | -7.00 | -38.00 | -396.00 | -0.1400 | -122.7330 | 0.0000 | 0.9790 | -0.1834 | -0.0145 | -0.0092 | 5.3496 | 54.00 | ||
| MoonLake Immunotherapeutics MLTX | 53.79 | 1.93 3.72% | 29 vs. 304 | 3,392.00 | 0.00 | -13.00 | -15.00 | -130.00 | -0.2200 | -55.6575 | 0.0000 | 0.0000 | 0.0000 | -0.0252 | -0.0242 | 61.5621 | 63.00 | ||
| Cerevel Therapeutics Holdings, Inc. CERE | 44.96 | 0.33 0.74% | 15,033 vs. 2,056 | 8,191.00 | 0.00 | -131.00 | -119.00 | -1,532.00 | -0.7300 | -14.5661 | 0.0000 | 0.0000 | 0.0000 | -0.2337 | -0.1170 | 10.1215 | 182.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.